The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence

English version České info

Among the Ebola viruses most species cause severe hemorrhagic fever in humans; however, Reston ebolavirus (REBOV) has not been associated with human disease despite numerous documented infections. While the molecular basis for this difference remains unclear, in vitro evidence has suggested a role for the glycoprotein (GP) as a major filovirus pathogenicity factor, but direct evidence for such a role in the context of virus infection has been notably lacking. In order to assess the role of GP in EBOV virulence, we have developed a novel reverse genetics system for REBOV, which we report here. Together with a previously published full-length clone for Zaire ebolavirus (ZEBOV), this provides a unique possibility to directly investigate the role of an entire filovirus protein in pathogenesis. To this end we have generated recombinant ZEBOV (rZEBOV) and REBOV (rREBOV), as well as chimeric viruses in which the glycoproteins from these two virus species have been exchanged (rZEBOV-RGP and rREBOV-ZGP). All of these viruses could be rescued and the chimeras replicated with kinetics similar to their parent virus in tissue culture, indicating that the exchange of GP in these chimeric viruses is well tolerated. However, in a mouse model of infection rZEBOV-RGP demonstrated markedly decreased lethality and prolonged time to death when compared to rZEBOV, confirming that GP does indeed contribute to the full expression of virulence by ZEBOV. In contrast, rREBOV-ZGP did not show any signs of virulence, and was in fact slightly attenuated compared to rREBOV, demonstrating that GP alone is not sufficient to confer a lethal phenotype or exacerbate disease in this model. Thus, while these findings provide direct evidence that GP contributes to filovirus virulence in vivo, they also clearly indicate that other factors are needed for the acquisition of full virulence.

Vyšlo v časopise: The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence. PLoS Pathog 8(8): e32767. doi:10.1371/journal.ppat.1002847
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002847

Souhrn

Zdroje

1. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Jahrling PB, et al. (2012) Filoviridae. In: King A, Adams M, Carstens E, Lefkowitz E, editors. Virus Taxonomy, Ninth Report of the International Committee on Taxonomy of Viruses. San Diego, CA: Elsevier Academic Press. 665–671.

2. TownerJS, SealyTK, KhristovaML, AlbarinoCG, ConlanS, et al. (2008) Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4: e1000212.

3. JahrlingPB, GeisbertTW, DalgardDW, JohnsonED, KsiazekTG, et al. (1990) Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 335: 502–505.

4. RollinPE, WilliamsRJ, BresslerDS, PearsonS, CottinghamM, et al. (1999) Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States. J Infect Dis 179 Suppl 1: S108–114.

5. WHO (1992) Viral haemorrhagic fever in imported monkeys. Wkly Epidemiol Rec 67 177–184.

6. MirandaME, KsiazekTG, RetuyaTJ, KhanAS, SanchezA, et al. (1999) Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis 179 Suppl 1: S115–119.

7. HayesCG, BuransJP, KsiazekTG, Del RosarioRA, MirandaME, et al. (1992) Outbreak of fatal illness among captive macaques in the Philippines caused by an Ebola-related filovirus. Am J Trop Med Hyg 46: 664–671.

8. BarretteRW, MetwallySA, RowlandJM, XuL, ZakiSR, et al. (2009) Discovery of swine as a host for the Reston ebolavirus. Science 325: 204–206.

9. MarshGA, HainingJ, RobinsonR, FoordA, YamadaM, et al. (2011) Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis 204 Suppl 3: S804–809.

10. KobingerGP, LeungA, NeufeldJ, RichardsonJS, FalzaranoD, et al. (2011) Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis 204: 200–208.

11. BauschDG (2011) Ebola virus as a foodborne pathogen? Cause for consideration, but not panic. J Infect Dis 204: 179–181.

12. Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, et al. (2001) Filoviridae - Marburg and Ebola viruses. In: Knipe D, Hoewley P, editors. Fields Virology. 4 ed. Philadelphia, PA: Lippincott Williams and Wilkins. 1279–1304.

13. KuhnJH, DoddLE, Wahl-JensenV, RadoshitzkySR, BavariS, et al. (2011) Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror 9: 361–371.

14. CDC (1990) Update: filovirus infection in animal handlers. MMWR Morb Mortal Wkly Rep 39: 221.

15. MirandaME, WhiteME, DayritMM, HayesCG, KsiazekTG, et al. (1991) Seroepidemiological study of filovirus related to Ebola in the Philippines. Lancet 337: 425–426.

16. WHO (2009) Outbreak news. Ebola Reston in pigs and humans, Philippines. Wkly Epidemiol Rec 84: 49–50.

17. YaddanapudiK, PalaciosG, TownerJS, ChenI, SariolCA, et al. (2006) Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J 20: 2519–2530.

18. BeckerY (1995) Retrovirus and filovirus “immunosuppressive motif” and the evolution of virus pathogenicity in HIV-1, HIV-2, and Ebola viruses. Virus Genes 11: 191–195.

19. VolchkovVE, BlinovVM, NetesovSV (1992) The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett 305: 181–184.

20. NeumannG, FeldmannH, WatanabeS, LukashevichI, KawaokaY (2002) Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 76: 406–410.

21. NeumannG, GeisbertTW, EbiharaH, GeisbertJB, Daddario-DiCaprioKM, et al. (2007) Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol 81: 2995–2998.

22. Alazard-DanyN, VolchkovaV, ReynardO, CarbonnelleC, DolnikO, et al. (2006) Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol 87: 1247–1257.

23. YangZY, DuckersHJ, SullivanNJ, SanchezA, NabelEG, et al. (2000) Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6: 886–889.

24. VolchkovVE, VolchkovaVA, MuhlbergerE, KolesnikovaLV, WeikM, et al. (2001) Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291: 1965–1969.

25. GrosethA, FeldmannH, TheriaultS, MehmetogluG, FlickR (2005) RNA polymerase I-driven minigenome system for ebola viruses. J Virol 79: 4425–4433.

26. RayRB, BasuA, SteeleR, BeyeneA, McHowatJ, et al. (2004) Ebola virus glycoprotein-mediated anoikis of primary human cardiac microvascular endothelial cells. Virology 321: 181–188.

27. SullivanNJ, PetersonM, YangZY, KongWP, DuckersH, et al. (2005) Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol 79: 547–553.

28. ZampieriCA, FortinJF, NolanGP, NabelGJ (2007) The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J Virol 81: 1230–1240.

29. BrayM (2001) The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 82: 1365–1373.

30. FeldmannH, VolchkovVE, VolchkovaVA, KlenkHD (1999) The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch Virol Suppl 15: 159–169.

31. TakadaA, KawaokaY (2001) The pathogenesis of Ebola hemorrhagic fever. Trends Microbiol 9: 506–511.

32. HoenenT, GrosethA, FalzaranoD, FeldmannH (2006) Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med 12: 206–215.

33. DolnikO, VolchkovaV, GartenW, CarbonnelleC, BeckerS, et al. (2004) Ectodomain shedding of the glycoprotein GP of Ebola virus. Embo J 23: 2175–2184.

34. FrancicaJR, Varela-RohenaA, MedvecA, PlesaG, RileyJL, et al. (2010) Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog 6: e1001098.

35. Fisher-HochSP, BrammerTL, TrappierSG, HutwagnerLC, FarrarBB, et al. (1992) Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis 166: 753–763.

36. BrayM, DavisK, GeisbertT, SchmaljohnC, HugginsJ (1999) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 179 Suppl 1: S248–258.

37. VolchkovVE, ChepurnovAA, VolchkovaVA, TernovojVA, KlenkHD (2000) Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 277: 147–155.

38. BrayM, DavisK, GeisbertT, SchmaljohnC, HugginsJ (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178: 651–661.

39. EbiharaH, TakadaA, KobasaD, JonesS, NeumannG, et al. (2006) Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2: e73.

40. SubbotinaE, DadaevaA, KachkoA, ChepurnovA (2010) Genetic factors of Ebola virus virulence in guinea pigs. Virus Res 153: 121–133.

41. de WitE, MunsterVJ, MetwallySA, FeldmannH (2011) Assessment of rodents as animal models for Reston ebolavirus. J Infect Dis 204 Suppl 3: S968–972.

42. RaymondJ, BradfuteS, BrayM (2011) Filovirus infection of STAT-1 knockout mice. J Infect Dis 204 Suppl 3: S986–990.

43. DeSancho M, Pastores S (2007) The Liver and Coagulation. In: Rodes J, Benhamou JP, Blei A, Reichen J, Rizzetto M, editors. Oxford, UK: Blackwell Publishing Ltd. 255–253.

44. BrayM, HatfillS, HensleyL, HugginsJW (2001) Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 125: 243–253.

45. WarfieldKL, BradfuteSB, WellsJ, LoftsL, CooperMT, et al. (2009) Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 83: 6404–6415.

46. AlvarezCP, LasalaF, CarrilloJ, MunizO, CorbiAL, et al. (2002) C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 76: 6841–6844.

47. TakadaA, FujiokaK, TsuijiM, MorikawaA, HigashiN, et al. (2004) Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 78: 2943–2947.

48. ChanSY, EmpigCJ, WelteFJ, SpeckRF, SchmaljohnA, et al. (2001) Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106: 117–126.

49. ShimojimaM, TakadaA, EbiharaH, NeumannG, FujiokaK, et al. (2006) Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol 80: 10109–10116.

50. KondratowiczAS, LennemannNJ, SinnPL, DaveyRA, HuntCL, et al. (2011) T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A 108: 8426–8431.

51. TheriaultS, GrosethA, NeumannG, KawaokaY, FeldmannH (2004) Rescue of Ebola virus from cDNA using heterologous support proteins. Virus Res 106: 43–50.

52. GrosethA, ChartonJE, SauerbornM, FeldmannF, JonesSM, et al. (2009) The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified. Virus Res 140: 8–14.

53. LuchtA, GrunowR, MollerP, FeldmannH, BeckerS (2003) Development, characterization and use of monoclonal VP40-antibodies for the detection of Ebola virus. J Virol Methods 111: 21–28.

54. ReedLJ, MuenchH (1938) A simple method of estimating fifty percent endpoint. Am J Hyg 27: 493–497.

55. MarziA, EbiharaH, CallisonJ, GrosethA, WilliamsKJ, et al. (2011) Vesicular Stomatitis Virus-Based Ebola Vaccines With Improved Cross-Protective Efficacy. J Infect Dis 204: S1066–S1074.